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Abstract
Introduction: Synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome is a rare dis-
order. The etiology remains unknown and the treatment is still empirical. Synovitis is one of the
major manifestations, but information on histopathological features is still lacking. In this case, we
investigated the histopathological features of SAPHO syndrome synovitis.
Case presentation: We present the case of a 53-year-old Japanese woman with SAPHO syndrome
accompanied by marked knee synovitis and palmoplantar pustulosis. We found abundant sterile
joint fluid in the right knee, and a blood test showed abnormally high values of C-reactive protein
(17.26 mg/dl) and matrix metalloproteinase-3 (>800 ng/ml). Arthroscopic surgery revealed marked
proliferation of villous synovial tissues similar to rheumatoid arthritis and standard microscopic
findings were also similar to rheumatoid arthritis. Furthermore, for the first time, we demonstrated
by immunohistochemistry the expression of tumor necrosis factor-alpha (TNF-a) converting
enzyme, TNF-a and matrix metalloproteinase-3 in the proliferated synovial lining cells. After
arthroscopic synovectomy, her knee symptoms immediately diminished and laboratory data (matrix
metalloproteinase-3 and C-reactive protein) normalized within 2 weeks of surgery.
Conclusion: We demonstrate the expression of TNF-a converting enzyme, TNF-a and matrix
metalloproteinase-3 in SAPHO syndrome synovitis for the first time and also show, both macro- and
microscopically, the similarity between SAPHO syndrome and rheumatoid arthritis synovitis. These
new findings support the recently reported successful treatment of SAPHO syndrome with
antirheumatic drugs, especially with anti-TNF-a agents.
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Synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO)
syndrome is a rare disorder characterized by osteoarticular
and dermatological manifestations, and was first
proposed by Chamot et al. [1]. The pathogenesis of SAPHO
syndrome has not been determined, thus a variety of
therapeutic approaches exist. Treatment remains empirical
with non-steroidal anti-inflammatory drugs (NSAIDs) and
analgesics being the first-line drugs; results are inconsis-
tent and usually inconclusive. Among other drugs, disease
modifying anti-rheumatic drugs (DMARDs) such as
sulfasalazine and methotrexate are the most frequently
employed, but results are also inconsistent. Recently,
positive outcomes have been obtained with bisphonates
via their anti-osteoclastic effect and anti-inflammatory
action, which are related to their suppressive effect on
tumor necrosis factor-alpha (TNF-a) [2]. Moreover, some
authors have reported the effectiveness of new DMARDs,
anti-TNF-a agents, especially for osteoarticular manifesta-
tions of SAPHO syndrome [3-7]. As has been shown in
rheumatoid arthritis (RA), proliferated synovium is a
major source of proinflammatory cytokines and protei-
nases. TNF-a is a key cytokine, which triggers the
inflammatory cascade and stimulates the production of
matrix degradable proteinases such as matrix metallopro-
teinases (MMPs) [8]. TNF-a converting enzyme (TACE)
processes a membrane form of TNF-a to a soluble form
[9], and the binding of the latter form to TNF receptors
triggers pathological events in RA. These findings indicate
that synovitis and the processing of TNF-a by TACE are
very important aspects in the pathogenesis of SAPHO
syndrome. However, detailed information on the patho-
logical features of synovitis in SAPHO syndrome is still
lacking.
In this report, we describe a patient with SAPHO
syndrome accompanied by marked knee synovitis. We
demonstrate the expression of TACE, TNF-a and MMP-3
in SAPHO syndrome synovitis for the first time and also
show the similarity between SAPHO syndrome and RA
synovitis.
Case presentation
A 53-year-old Japanese woman first presented to a
neighborhood clinic in 2001 with palmoplantar pustu-
losis. In January 2005, the patient experienced lower back
pain, and a compression fracture of the fifth lumbar
vertebral body was diagnosed at the same clinic. In May
2005, the first episode of painful swelling of her right knee
occurred. For the knee pain, conventional therapy with
NSAIDs was applied. In June 2006, she presented to our
department for the first time with persistent swelling and
pain in her right knee, and could not walk without a
T-cane (walking stick). Physical examination showed
marked patellar ballottement with local heat, and the
range of motion was 0–100 degrees. A knee puncture
yielded 20 ml of yellow cloudy joint fluid, but cultures for
bacteria were negative. At the time, mild, dull lower back
pain was still continuing but no other joint pain, including
in the costa-sterno-clavicular joint, was found. Palmo-
plantar pustulosis was observed in both her palms and her
soles. Laboratory tests showed elevated indices of inflam-
mation: erythrocyte sedimentation rate 87 mm/hour,
C-reactive protein (CRP) level 17.26 mg/dl (normal
<0.30 mg/dl) and an abnormally high value of matrix
metalloproteinase (MMP)-3 >800 ng/ml (normal range
17.3-59.7 ng/ml). Rheumatoid factor was negative. Radio-
graphic study revealed that the right knee and the lumbar
spine seemed to be normal. Magnetic resonance imaging
(MRI) revealed knee synovitis and bone marrow edema
at the fifth lumbar vertebral body, compatible with sterile
inflammation.
In July 2006, arthroscopic surgery was performed for knee
synovitis. Intra-operative findings showed marked prolif-
eration of villous contoured synovial tissues with rich
blood circulation similar to RA (Figure 1a). Continuous
paraffin sections of biopsied synovial tissues were used for
histopathological analyses, and standard microscopic
study showed hyperplastic synovitis with lymphoid
nodules and many blood vessels similar to RA (Figure 1b).
Immunohistochemistry revealed the expression of TACE
(Figure 1c, e), TNF-a (Figure 1g) and MMP-3 (Figure 1d, f)
in synovial cells of the lining layer. TACE and TNF-a were
expressed dominantly in CD68 positive synovial cells of
the superficial lining layer, whereas MMP-3 was expressed
in CD68 negative synovial cells of the deep lining layer
(Figure 1e-h). Primary antibodies used for these analyses
were polyclonal antibodies for TACE (sc-25782; Santa
Cruz Biotechnology, USA), TNF-a (654250; Calbiochem,
Germany), monoclonal antibodies for MMP-3 (55-2A2;
Daiichi Fine Chemical Co., Japan) and CD68 (M0814;
DakoCytomation, Denmark).
After arthroscopic synovectomy, her knee symptoms
immediately diminished and laboratory data (MMP-3
and CRP) normalized within 2 weeks of surgery. In the
2-year follow-up period, there was no recurrence of
synovitis, no exacerbation of palmoplantar pustulosis,
and MMP-3 and CRP levels remained normal.
Discussion
We investigated the histopathological features of SAPHO
syndrome synovitis in our patient. Macroscopic findings
showed marked proliferation of villous contoured syno-
vial tissues with rich blood circulation. Microscopic
findings showed hyperplastic synovitis with lymphoid
nodules and many blood vessels. Further immunohisto-
chemistry showed that TACE and TNF-a were expressed
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cells of the superficial lining layer while MMP-3 was
expressed in CD68-negative fibroblast-like synovial cells
of the deep lining layer. These histopathological features
overlapped withthoseof RA synovitis.However, theextent
of each microscopic feature, such as the hyperplasticity of
the lining layers, lymphoid nodules and vascular density,
seems to be more marked in RA than in SAPHO syndrome.
Although it is difficult to compare our findings with past
cases due to lack of reports with detailed histopathological
analyses of SAPHO syndrome synovitis, the similarity of
the histopathological features between SAPHO syndrome
and RA indicates that, at least partially, they have a
common synovial pathogenesis.
The treatment of SAPHO syndrome remains empirical, but
recently some successful experiences with bisphonates and
anti-TNF-a agents have been reported. It is speculated that
these drugs act via the suppression of TNF-a action [2].
TACE is a key proteinase in the processing of TNF-a [9]
and the processed form can bind to TNF receptors and
activate various pathological events including the produc-
tion of MMPs. In our patient, the highly elevated serum
MMP-3 level was normalized after arthroscopic synovect-
omy. Several studies have indicated that TACE levels are
elevated in RA joints compared with osteoarthritis or
normal articulations, suggesting that abnormal TACE
activity contributes to TNF-a action in RA pathogenesis.
The expression of TACE, TNF-a and MMP-3, therefore,
encourages us to speculate that TACE plays a role in the
pathogenesis of SAPHO syndrome synovitis through the
processing of TNF-a, which triggers a cascade of patho-
logical events through a mechanism similar to RA. To the
best of our knowledge, 10 cases of SAPHO syndrome
treated with anti-TNF-a agents have been described, all of
them showing a sustained response on osteoarticular
manifestations [3-7], but were not favorable for cutaneous
manifestations in some cases [5]. The reasons for the
negative effects on cutaneous manifestations have not yet
been determined. It is premature to exclude anti-TNF-a
agents from the therapeutic options for SAPHO syndrome
because examples of the application of these agents have
been limited to recalcitrant cases. Further investigations
are clearly needed to elucidate this rare and complicated
disorder and the expression of TACE, TNF-a and MMP-3
in the synovium may provide an important clue for the
development of a new therapeutic strategy for SAPHO
syndrome.
Conclusion
We have demonstrated the expression of TACE, TNF-a and
MMP-3 in SAPHO syndrome synovitis for the first time
Figure 1. Macro- and microscopic findings of synovitis-
acne-pustulosis-hyperostosis-osteitis syndrome synovitis.
Note that rheumatoid arthritis-like villous contoured
synovial tissues with rich blood circulation are markedly
proliferated (a). Continuous paraffin sections were stained
with hematoxylin and eosin (b) or immunostained with
antibodies against tumor necrosis factor-alpha converting
enzyme (c, e), matrix metalloproteinase-3 (d, f), tumor
necrosis factor-alpha (g), or CD68 (h). Note that hyperplastic
synovitis with lymphoid nodules similar to rheumatoid
arthritis (b), and tumor necrosis factor-alpha converting
enzyme, tumor necrosis factor-alpha and matrix
metalloproteinase-3 are expressed in synovial lining cells (c-g).
Arrows, synovial lining cells. Scale bar, 100 μm.
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and RA synovitis. These new findings support the recently
reported successful treatment of osteoarticular manifesta-
tions of SAPHO syndrome with anti-TNF-a agents.
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